Picankibart treatment for stubborn hand and foot pustules
Part of Skin clinical trials.
This trial tests a new medication called picankibart for palmoplantar pustulosis, a skin condition causing painful pustules (small fluid-filled bumps) on the palms and soles. It's designed for people whose condition hasn't improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years old
- Confirmed diagnosis of palmoplantar pustulosis (bumpy, pustule-filled skin on hands and feet)
- Failed or had side effects from at least one standard systemic treatment given for 12–24 weeks
- Your doctor believes picankibart is a suitable option for you
- No active hepatitis B, hepatitis C, or tuberculosis infection
- Not pregnant and no plan to become pregnant in the next 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called bimekizumab for people with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal is to see if the drug can clear these pustules and improve symptoms.
This trial tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis (PPP), a skin condition with pustules on the palms and soles. The cream is applied daily for 16 weeks to see if it improves symptoms and is safe.
This trial tests a new oral medication, ivarmacitinib, for adults with palmoplantar pustulosis (PPP) who haven't gotten better with standard treatments. It aims to see if the drug is safe and effective for reducing the painful pustules on the palms and soles.
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
This trial tests a new injectable drug, Stapokibart, for people with moderate to severe bullous pemphigoid, a blistering skin condition. The goal is to see if the drug can help reduce blistering and itching.
This study tests a new drug (Xeligekimab) for people with moderate to severe palmoplantar pustulosis — a condition causing painful blisters on the hands and feet. It may be an option if other treatments haven't worked well.
Hear when a new Palmoplantar Pustulosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.